Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.48 |
| ▸ | CPT2 | P23786 | 2/20 | 0.44 |
| ▸ | CPT1A | P50416 | 2/20 | 0.44 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL31344148 | 0.88 | CA1 (0.48) | CA2SLC22A1CPT2CPT1ACPT1B | |
| Tetrabuthylammonium SCHEMBL21833984 | 0.85 | SLC22A1 (0.44) | CA2SLC22A1CPT2CPT1ACPT1B | |
| Tetrabuthylammonium SCHEMBL105361 | 0.85 | CA1 (0.55) | SLC22A1CPT2CPT1ACPT1BCA1 | |
| Tetrabuthylammonium SCHEMBL1691312 | 0.81 | SLC22A1 (0.55) | CA2SLC22A1CA1SLC22A2 | |
| Tetrabuthylammonium SCHEMBL5874718 | 0.81 | CA4 (0.59) | SLC22A1CPT2CPT1ACPT1BCA1 | |
| Tetrabuthylammonium SCHEMBL230091 | 0.81 | SLC22A1 (0.44) | SLC22A1CPT2CPT1ACPT1BSLC22A2 | |
| Tetrabuthylammonium SCHEMBL107562 | 0.81 | SLC22A1 (0.60) | SLC22A1CA1SLC22A2 | |
| Tetrabuthylammonium SCHEMBL106861 | 0.80 | SLC22A1 (0.67) | SLC22A1SLC22A2 | |
| Tetrabuthylammonium SCHEMBL9008776 | 0.79 | SLC22A1 (0.43) | SLC22A1CPT2CPT1ACPT1BCA1 | |
| Tetrabuthylammonium SCHEMBL9094612 | 0.79 | CA4 (0.57) | SLC22A1CPT2CPT1ACPT1BCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058380-A1 | Novel aminobenzophenone compounds | OTTOSEN ERIK R | 2006-03-16 | — | — | US | disclosed |
| EP-1583735-A2 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004056762-A2 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058380-A1 | Novel aminobenzophenone compounds | NFKBIA, IL4I1, ALDH7A1 | CA2 4634/4885SLC22A1 1506/4885CPT2 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.